Treatment of Uterine Sarcoma in Perivascular Epithelioid Cell Tumor of the Female Genital Tract

This protocol covers uterine sarcoma arising in the setting of perivascular epithelioid cell tumor (PEComa) of the female genital tract — a rare mesenchymal tumor subtype that presents distinct management considerations, especially in locally advanced disease.

Clinical Scenario

PEComas are rare mesenchymal tumors that can occur in multiple sites, with gynecological PEComas making up 25% of cases. The rarity and specific biology of this subtype mean that standard uterine sarcoma pathways may not apply directly — particularly when locally advanced disease raises the prospect of significant surgical morbidity.

Treatment Approach

For locally advanced disease, a targeted systemic approach using an mTOR inhibitor class of agents is the strategy considered to manage disease while avoiding surgery with the potential for significant morbidity.

Full agent selection, sequencing, and clinical decision criteria are available in the complete protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ijgc-2024-005823

PEComas are rare mesenchymal tumors that can occur in multiple sites, with gynecological PEComas making up 25%.
For locally advanced disease, mTOR inhibitors can be considered to avoid surgery with the potential for significant morbidity (IV, B).
mTOR inhibitors, such as everolimus, sirolimus, and temsorolimus, have all been reported to have activity, with overall response rate of up to 40%.

View source ↗